CervoMed Q1 2024 Earnings Report $2.11 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast CervoMed EPS ResultsActual EPS-$0.41Consensus EPS -$0.46Beat/MissBeat by +$0.05One Year Ago EPSN/ACervoMed Revenue ResultsActual Revenue$2.35 millionExpected Revenue$2.00 millionBeat/MissBeat by +$350.00 thousandYoY Revenue GrowthN/ACervoMed Announcement DetailsQuarterQ1 2024Date5/14/2024TimeN/AConference Call ResourcesPress ReleaseCRVO Earnings HistoryPowered by CervoMed Earnings HeadlinesCervoMed downgraded to Neutral from Buy at H.C. WainwrightDecember 17, 2024 | markets.businessinsider.comHC Wainwright & Co. Downgrades CervoMed (CRVO)December 17, 2024 | msn.comDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. January 19, 2025 | Crypto 101 Media (Ad)CervoMed (CRVO) was downgraded to a Hold Rating at H.C. WainwrightDecember 17, 2024 | markets.businessinsider.comCervoMed announces inducement grants under Nasdaq lisitng ruleDecember 13, 2024 | markets.businessinsider.comCervoMed Inc.: CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 12, 2024 | finanznachrichten.deSee More CervoMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email. Email Address About CervoMedCervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.View CervoMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)HDFC Bank (1/21/2025)Charles Schwab (1/21/2025)Prologis (1/21/2025)3M (1/21/2025)Capital One Financial (1/21/2025)ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
